LY3437943, a triple receptor agonist: a phase 1b trial in people with type 2 diabetes
Urva S, Coskun T, Loh MT, et al.
Study overview
A 12-week phase 1b study enrolled 72 adults with type 2 diabetes. The authors reported an approximate six-day half-life for LY3437943 (retatrutide). Gastrointestinal events were common. This historical trial supports the half-life teaching example, not a personal regimen.
Results are specific to the study. This is an editorial summary, not personal treatment advice.
Study limitations
Small early-phase population, short follow-up and substantial discontinuation limit generalization. A population pharmacokinetic estimate is not an individual blood-level prediction, a safe washout interval, or evidence that a research vial matches the trial formulation.
About this summary
This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.